Toggle Main Menu Toggle Search

Open Access padlockePrints

Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial

Lookup NU author(s): Professor Naeem Soomro


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2021 The Authors BJU International © 2021 BJU InternationalObjectives: To test the feasibility of randomisation to radical prostatectomy (RP) plus pelvic lymphadenectomy in addition to standard-of-care (SOC) systemic therapy in men with newly diagnosed oligo-metastatic prostate cancer. Patients and Methods: A prospective, randomised, non-blinded, feasibility clinical trial with an embedded QuinteT Recruitment Intervention (QRI) to optimise recruitment was conducted in nine nationwide tertiary care centres undertaking high-volume robotic surgery. We aimed to randomise 50 men with synchronous oligo-metastatic prostate cancer within an 18-month recruitment period to SOC systemic therapy vs SOC plus RP (intervention arm). The main outcome measures were: ability to randomise patients, optimised by a QRI; EuroQoL five Dimensions five Levels (EQ-5D-5L) questionnaires to capture quality-of-life (QoL) data at baseline and 3 months post-randomisation; routine clinicopathological assessment to capture adverse events and prostate-specific antigen in both arms, plus standard perioperative parameters in the surgical arm. Results: A total of 51 men were randomised within 14 months (one was subsequently deemed ineligible), with 60–83% accrual rate in centres that recruited at least two patients. All patients completed the trial follow-up; one patient in the intervention arm subsequently did not undergo the surgical intervention and one in the SOC arm refused all therapies. The QRI positively impacted recruitment. QoL data showed similarly high functioning in both study arms. Surgery for men with oligo-metastatic prostate cancer was found to be safe and had similar impact on early functional outcomes as surgery for standard indication. Conclusion: It is feasible to randomise men with synchronous oligo-metastatic prostate cancer to a surgical intervention in addition to standard systemic therapies. While surgery appeared safe with no substantial impact on QoL in this feasibility study, a large randomised controlled trial is now warranted to examine treatment effectiveness of this additional component in the multimodality management of oligo-metastatic prostate cancer.

Publication metadata

Author(s): Sooriakumaran P, Wilson C, Rombach I, Hassanali N, Aning J, D Lamb A, Cathcart P, Eden C, Ahmad I, Rajan P, Sridhar A, Bryant RJ, Elhage O, Cook J, Leung H, Soomro N, Kelly J, Nathan S, Donovan JL, Hamdy FC

Publication type: Article

Publication status: Published

Journal: BJU International

Year: 2021

Volume: 48

Pages: 190-200

Online publication date: 16/12/2021

Acceptance date: 08/12/2021

ISSN (print): 1464-4096

ISSN (electronic): 1464-410X

Publisher: John Wiley and Sons Inc


DOI: 10.1111/bju.15669

PubMed id: 34878715


Altmetrics provided by Altmetric